First Tracks Biotherapeutics Inc
NASDAQ:TRAXBiotechnology
-$0.89 today
- Market cap
- $1.87B
- Beta
- 0.00
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$2.81
Volume 0.75M
Average 0.43M
TRAX Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
First Tracks Biotherapeutics IncNASDAQ: TRAX
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow grows 37.4% year over year
Q1 FY2026 financing cash flow of $7.85M rose 37.4% year over year.
Context
- Financing cash flow increased in 1 of the last 2 fiscal years.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 30.01M USD
- Year-over-year change
- -74.5%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 30.01M | -74.5% |
| FY2024 | 2024-12-31 | 117.52M | +234.9% |
| FY2023 | 2023-12-31 | (87.09M) | — |
Financing Cash Flow vs competitors
How TRAX compares with its peers on the latest reported figures
- TRAX's FY2025 financing cash flow of $30.01M is the 9th largest of the 10 companies compared; the peer median is $103.52M.
- Its year-over-year change of -74.5% is the 8th highest of 10, against a peer median of +24.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $596.22M | +24.1% | +103.3% | 8403.4% | |
| LTM Jun 2026 | $350.85M | +33009.9% | +443.0% | — | |
| LTM Mar 2026 | $254.22M | +330054.5% | -11.9% | — | |
| FY2025 | $142.01M | +71.6% | — | 10519.4% | |
| LTM Mar 2026 | $103.52M | +40.9% | +6.8% | — | |
| LTM Mar 2026 | $102.81M | -191.7% | — | 44.2% | |
| LTM Mar 2026 | $53.69M | -59.8% | — | — | |
| LTM Mar 2026 | $52.19M | -29.8% | — | 623.8% | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $30.01M | -74.5% | — | — |
CLYMClimb Bio, Inc. | LTM Mar 2026 | $16K | -100.0% | — | — |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding TRAX) | $103.52M | +24.1% | +55.1% | 4513.6% | |
Competitors are the stored peer set for TRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Net Income | (106.15M) | (163.71M) | (166.09M) |
| Depreciation & Amortization | 2.38M | 2.4M | 2.42M |
| Deferred Income Tax | 0 | 0 | 0 |
| Stock-Based Compensation | 18.39M | 26.83M | 32.3M |
| Change in Working Capital | 2.9M | 18.99M | (1.52M) |
| Accounts Receivables | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 |
| Accounts Payables | 8.39M | 17.81M | 0 |
| Other Working Capital | (5.49M) | 1.18M | (1.52M) |
| Other Non-Cash Items | (10.52M) | (10.31M) | (10.04M) |
| Operating Cash Flow | (93M) | (125.81M) | (142.93M) |
| Capital Expenditures | (807K) | (358K) | (87K) |
| Acquisitions (Net) | 0 | 0 | 0 |
| Purchases of Investments | (303.92M) | (380.38M) | 0 |
| Sales of Investments | 449.48M | 476.13M | 0 |
| Other Investing Activities | 0 | 0 | 228.12M |
| Investing Cash Flow | 144.75M | 95.4M | 228.03M |
| Debt Repayment | 0 | 0 | 0 |
| Common Stock Issued | 0 | 117.52M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 30.01M |
| Financing Cash Flow | (87.09M) | 117.52M | 30.01M |
| Effect of Forex Changes | 0 | 0 | 0 |
| Net Change in Cash | (35.34M) | 87.12M | 115.12M |
| Free Cash Flow | (93.81M) | (126.16M) | (143.01M) |
First Tracks Biotherapeutics Inc
NASDAQ:TRAX
Intrinsic Alpha fair value
Locked
Current Price
$44.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.